Interactions between chemotherapy, endocrine therapy and radiation

Acta Oncologica

Volumn 41, Issue 7-8, 2002, Pages 635-638

  Glimelius, Bengt ^a   Nordenskjöld, Bo ^b   Kjellén, Elisabeth ^c   Zackrisson, Björn ^d   Brahme, Anders ^e   Carlsson, Jörgen ^e   Forssell Aronsson, Eva ^e   Hellström, Mikael ^e   Johansson, Karl Axel ^e   Littbrand, Bo ^e   Mattsson, Sören ^e   Stenerlöw, Bo ^e   Turesson, Ingela ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; ENDOCRINOLOGY; RADIOTHERAPY; TUMORS;

ANTI-TUMOR DRUGS;

CHEMOTHERAPY;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GROWTH FACTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 12244270373     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602321028247     Document Type: Article

References (24)

1. Zackrisson B, Kjellén E, Glimelius B, Carlsson J, Littbrand B, Turesson I. Sensitising and protective substances in radiation therapy and predictive assays. Acta Oncol 2002; 41: 615-22.
2. Mason KA, Komaki R, Cox JD, et al. Biology-based combined-modality radiotherapy: workshop report. Int J Radiat Oncol Biol Phys 2001; 50: 1079-89.
3. vonder Maase H. Combined radiotherapy and chemotherapy. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. Oxford: Oxford University Press, 2001: 489-509.
4. Pignon JP, Bourkis J, Domenge C, et al. Chemotherapy added to locoregional treatment of head and neck squamous carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949-55.
5. Sternberg CN, Parmar MKB. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol 2001; 19: 21-6.
6. Rose PG, Bundy BN. Chemoradiation for locally advanced cervical cancer: does it help? J Clin Oncol 2002; 20: 891-3.
7. Schilsky RL. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Sem Oncol 1992; 19 (Suppl 11): 2-7.
8. Smalley SR, Kimler BF, Evans RG. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 20: 207-11.
9. Formenti SC, Danenberg PV. Paclitaxel-induced radiosensitization: myth or reality? Adv Oncol 1999; 5: 125-9.
10. von der Maase H. Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour. Radiother Oncol 1986; 7: 47-68.
11. Medical Research Council Prostate Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46.
12. Granfors T, Modig H, Damber J-E, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized trial. J Urol 1998; 159: 2030-4.
13. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001; 51: 1002-7.
14. Bentzen SM, Skoczylas JZ, Overgaard M, et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88: 918-22.
15. Sertoli MR, Pronzato P, Venturini M, et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol 2002; 21: Abstr 182.
16. Harari PM, Huang S-M. Augmentation of radiation therapy after growth factor signaling blockade. Proc Am Soc Clin Oncol, Educational Book 2001; 42-6.
17. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8.
18. Nasu S, Ang K, Fan Z, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51: 474-7.
19. Travis L. Therapy-associated secondary solid cancer. Acta Oncol 2002; 41: 323-33.
20. Glimelius B. Chemoradiotherapy for rectal cancer - is there an optimal combination? Ann Oncol 2001; 12: 1039-45.
21. Albertsson M. Chemoradiotherapy of esophageal cancer. Acta Oncol 2002; 41: 118-23.
22. Van Houtte P. The role of radiotherapy and the value of combined treatment in lung cancer. Eur J Cancer 2001; 37 (Suppl 7): S91-8.
23. Coleman CN. Radiation oncology - Linking technology and biology in the treatment of cancer. Acta Oncol 2002; 41: 6-13.
24. Turesson I, Stenerlöw B, Carlsson J, et al. and the Swedish Cancer Society Investigation Group. Radiobiological response to radiation. Acta Oncol 2003; 42: (in press).